Pfizer began studying an new mRNA Flu Vaccine
U.S. pharmaceutical company Pfizer announced that it has begun testing a flu vaccine based on mRNA technology, the same one used in its coronavirus vaccine.
Already the first volunteer was vaccinated, according to Reuters agency. The trial will be performed in the U.S. with healthy individuals 65 to 85 years of age. The initial objective is, as usual, to check the safety of the vaccine and then its effectiveness in terms of immune response.
- Computer sales decreased significantly due coronavirus
- AI System can diagnose lung cancer up to a year earlier
“The Covid-19 pandemic has allowed us to seize the huge scientific opportunity of mRNA. The flu remains an area where we need vaccines,” said Kathrin U. Jansen, head of Pfizer’s research and development department.